


## nAMD vision loss during COVID

## SUPPLEMENTARY MATERIALS




**Figure 1.** Average distribution of visual acuities across all iterations in the simulation process at baseline (A) and at one year (B) for the full EMR nAMD cohort and under four modelled conditions: no, 3, 6 and 9-months treatment delay, including eyes with VA ≤25 letters (≤6/96 Snellen) at baseline

## nAMD vision loss during COVID

	<b>No treatment delay</b>	<b>3-month delay</b>	<b>6-month delay</b>	<b>9-month delay</b>
<b>Mean one-year VA</b>	58.3 letters (57.1 - 59.5)	53.6 letters (52.4 - 55.0) <i>[-4.7 letters (<math>p &lt; 0.001</math>)]</i>	51.5 letters (50.2 - 52.8) <i>[-6.8 letters (<math>p &lt; 0.001</math>)]</i>	50.1 letters (48.7 - 51.3) <i>[-8.2 letters (<math>p &lt; 0.001</math>)]</i>
<b>% <math>\leq 35</math> letters</b>	14.5% (12.3 - 16.8)	21.4% (18.9 - 23.9) <i>[+6.9% (<math>p &lt; 0.001</math>)]</i>	25.0% (22.2 - 27.7) <i>[+10.5% (<math>p &lt; 0.001</math>)]</i>	27.7% (25.0 - 30.7) <i>[+13.2% (<math>p &lt; 0.001</math>)]</i>
<b>% <math>\leq 55</math> letters</b>	39.1% (35.9 - 42.2)	49.4% (46.2 - 52.5) <i>[+10.3% (<math>p &lt; 0.001</math>)]</i>	54.0% (50.6 - 57.3) <i>[+14.9% (<math>p &lt; 0.001</math>)]</i>	56.9% (53.7 - 60.2) <i>[+17.8% (<math>p &lt; 0.001</math>)]</i>
<b>% <math>\geq 70</math> letters</b>	35.2% (32.3 - 38.2)	26.6% (24.0 - 29.5) <i>[-8.6% (<math>p &lt; 0.001</math>)]</i>	23.4% (20.8 - 26.0) <i>[-11.8% (<math>p &lt; 0.001</math>)]</i>	21.6% (19.0 - 24.3) <i>[-13.6% (<math>p &lt; 0.001</math>)]</i>

**sTable 1.** Average (95% bootstrap confidence interval) simulated one-year visual outcomes under each of the four modelled conditions - including unchanged one-year visual acuity. Comparisons with the no treatment delay model are provided in italics.

## nAMD vision loss during COVID



**Figure 2.** Overlaid histograms showing the range of simulated one-year visual acuity (VA) outcomes across 1000 iterations for the no delay, 3, 6 and 9-month treatment delay models including eyes with VA  $\leq 25$  letters ( $\leq 6/96$  Snellen) at baseline. 'Count' on the y-axis refers to the number of iterations that generated a visual outcome estimate at the values on the x-axis. A: mean one-year VA (dashed grey vertical lines illustrate

## nAMD vision loss during COVID

Snellen equivalents). B: percentage of eyes with  $\leq 35$  letters ( $\leq 6/60$  Snellen). C: percentage of eyes with  $\leq 55$  letters ( $\leq 6/24$  Snellen) D: percentage of eyes with  $\geq 70$  letters ( $\geq 6/12$  Snellen).